Adderall Shortage Caused by DEA Quotas on Controlled Substances
The Adderall shortage, linked to DEA quotas, impacts ADHD patients. Despite efforts to address the issue, the DEA's inflexible approach exacerbates the crisis, prompting calls for systemic reform to alleviate suffering.
Read original articleThe Adderall shortage, affecting ADHD patients, is attributed to DEA quotas on controlled substances. The DEA sets production and distribution limits for drug companies annually, leading to ongoing medication scarcity. Despite public outcry and FTC involvement, the DEA maintains its restrictive approach, impacting patients reliant on stimulant medications. The DEA's actions stem from concerns about diversion and abuse, despite limited evidence supporting these claims. The agency's inflexible quota system fails to adapt to changing needs, exacerbating the shortage. Efforts to blame drug companies, raw material shortages, and telemedicine clinics have not resolved the issue. The DEA's reluctance to adjust quotas despite the evident consequences has prolonged the crisis. Stakeholders are urged to provide feedback to the FTC and HHS to address the medication shortage. The DEA's role in perpetuating the scarcity underscores the need for systemic reform to alleviate the suffering of those dependent on ADHD medications.
Related
The Opaque Industry Inflating Prices for Prescription Drugs
Pharmacy Benefit Managers (PBMs) like CVS Health, Cigna, and UnitedHealth Group are criticized for increasing prescription drug costs in the US. Despite claims of cost reduction, PBMs allegedly steer towards expensive drugs, charge high markups, and prioritize financial gains over patients. Lawmakers are scrutinizing their practices for potential price inflation and anticompetitive behavior.
Next-generation psychedelics: should new agents skip the trip?
Companies are investing in next-generation psychedelics to enhance mental health treatment, focusing on reducing psychoactive effects while maintaining therapeutic benefits. Despite expanding interest and investments, questions persist about efficacy and cost-effectiveness.
Company linked to federal execution spree will no longer produce key drug
A Connecticut chemicals manufacturer, Absolute Standards, halts pentobarbital production due to pressure from lawmakers and activists. This decision may affect future executions, prompting debates on lethal injection ethics.
Hims & Hers Selling GLP-1 Injection That’s Not FDA Approved, From Shady Supplier
Hims & Hers sells non-FDA approved weight loss drug through loophole, raising concerns about patient safety, legality, and supplier's history of fraud. Executives sold shares amid risks of legal consequences.
Synthetic psychedelic found in candies linked to seizures, intubation
A synthetic psychedelic compound and toxic plant compounds found in Diamond Shruumz candies caused severe illnesses in 39 cases across 20 states. FDA advises against consumption and is discussing a possible recall with the company.
If you don't know, all of the steps listed above are what my medication helps me accomplish. Its like they designed a wheelchair store with a full flight of stairs in order to get in.
I'll eat my hat if this is actually true. US college students are about half white right now. The other half, plus all women, plus all people who don't go to college, plus everyone who isn't 18 to 22, are 10% of the illicit-stimulant market combined? This has to be something made-up to attack what they feel is an outgroup.
We saw that production and consumption of opiates was far too high, eventually leading to the bankruptcy of Purdue Pharma. In that case it seems like the DEA was not taking a strong enough regulatory role, leading to much harm to Americans.
Are we facing an upcoming epidemic of amphetamine addiction and the DEA is holding it back, or is the DEA causing more harm through regulation of production? It’s impossible to tell from this article alone, but it seems clear we need at least some regulation of production, since the pharmaceutical industry cannot completely self regulate.
https://archive.ph/2024.04.17-223802/https://www.nytimes.com...
Full disclosure, he was my doc and diagnosed me with ADHD. I kind of think the whole thing is a scam now in large part due to this.
I have to have a special registration card, separate from any other medical insurance or ID. When I get fill the prescription I must present photo ID, can only get a very limited amount etc. If my medical details insurance change for in any (for example an address change) my ability to fill the prescription is instantly cancelled until those details are updated (even though for any other medication this is not the case. For other medication there is a simple way to handle these changes retroactively, but not for ADHD medication).
Multiple times I've been without medication because of these traps. Not only that, they are rare and unusual enough that health care professionals don't know about them and sometimes give you incorrect advice.
Related
The Opaque Industry Inflating Prices for Prescription Drugs
Pharmacy Benefit Managers (PBMs) like CVS Health, Cigna, and UnitedHealth Group are criticized for increasing prescription drug costs in the US. Despite claims of cost reduction, PBMs allegedly steer towards expensive drugs, charge high markups, and prioritize financial gains over patients. Lawmakers are scrutinizing their practices for potential price inflation and anticompetitive behavior.
Next-generation psychedelics: should new agents skip the trip?
Companies are investing in next-generation psychedelics to enhance mental health treatment, focusing on reducing psychoactive effects while maintaining therapeutic benefits. Despite expanding interest and investments, questions persist about efficacy and cost-effectiveness.
Company linked to federal execution spree will no longer produce key drug
A Connecticut chemicals manufacturer, Absolute Standards, halts pentobarbital production due to pressure from lawmakers and activists. This decision may affect future executions, prompting debates on lethal injection ethics.
Hims & Hers Selling GLP-1 Injection That’s Not FDA Approved, From Shady Supplier
Hims & Hers sells non-FDA approved weight loss drug through loophole, raising concerns about patient safety, legality, and supplier's history of fraud. Executives sold shares amid risks of legal consequences.
Synthetic psychedelic found in candies linked to seizures, intubation
A synthetic psychedelic compound and toxic plant compounds found in Diamond Shruumz candies caused severe illnesses in 39 cases across 20 states. FDA advises against consumption and is discussing a possible recall with the company.